Posted by Michael Wonder on 18 Oct 2023
Hyloris announces US FDA approval of Maxigesic IV
18 October 2023 - Maxigesic IV, a potent non-opioid painkiller, to be marketed in the US under the tradename Combogesic IV.
Hyloris Pharmaceuticals today announces Maxigesic IV has been approved for the relief of mild to moderate pain and for the management of moderate to severe pain as an adjunct to opioid analgesics in adults, where an intravenous route of administration is considered clinically necessary.
